© 2026 Sinochem Nanjing Corporation,
All Right Reserved
In the early days of hepatitis C treatment, regimens pushed patients through months of grueling injections, heavy side effects, and patchy results. Many remember the interferon era, which left countless hoping for a gentler option. After years of research into nucleotide analogues, scientists at Pharmasset made an important breakthrough with a compound that would soon chase viral replication at its root. Their work sparked Gilead Sciences’ interest, and by 2013, the world saw the launch of Sofosbuvir under the brand name Sovaldi. This new drug changed the landscape, shifting hepatitis C therapy from six-month gambles toward shorter, mostly painless oral combinations with over 90% cure rates. Its coming signaled a move from a chronic, often-fatal disease toward widespread hope for complete eradication.
Sofosbuvir sits at the core of modern antiviral regimens. The drug, classified as a nucleotide analog, blocks the activity of HCV's RNA polymerase, short-circuiting viral reproduction at the earliest step. It shows oral bioavailability, requires only a single daily dose, and does not typically need boosting or food restrictions. Sofosbuvir started out branded as Sovaldi, but soon became a foundation for combination pills like Harvoni and Epclusa. Physicians and pharmacists note how this design reduced the pill burden and ushered in a new standard where people with chronic HCV could expect outcomes once thought impossible. The global reach has been remarkable, with over 100 countries approving various forms, offering both originator brands and generic options.
Sofosbuvir presents as a white to off-white crystalline powder, showing moderate solubility in water. At the molecular level, its structure packs a fluorinated uridine monophosphate analog, with the IUPAC name (S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydrofuran-2-yl)methoxy)-(phenoxy)phosphorylamino)propanoate. The compound’s molecular formula reads as C22H29FN3O9P, clocking in with a molecular weight of 529.45 g/mol. Melting point sits around 162–164°C. Chemical stability under normal conditions is good, a necessity for real-world use.
Each sofosbuvir tablet typically contains 400 mg of the active pharmaceutical ingredient, along with inactive elements to ensure stability, absorption, and manufacturability. Tablets appear as yellow, capsule-shaped films, clearly labeled for dose identification, with each pill marking its Gilead or generic source. Packaging sports tamper-evidence and child resistance, backed by regulatory requirements in every market where it's sold. Pharmacies supply detailed inserts, including instructions for dosing, comprehensive safety profiles, storage guidelines (store at 25°C, avoid excessive moisture), and up-to-date warnings on potential interactions with other drugs – especially potent inducers of certain liver enzymes.
The original synthetic route draws on complex organic chemistry, using nucleotide chemistry principles developed for decades. Synthesis starts from a pyrimidine base, protected appropriately, then coupled stepwise with a sugar moiety under stereochemical control. Multiple protection and deprotection cycles, along with key fluorination and phosphorylating steps, end with a prodrug esterification to enhance oral activity. Commercial production refines these steps for efficiency and purity, trimming waste and energy use to comply with current regulatory standards for pharmaceutical manufacturing. Each batch undergoes strict cGMP protocols including verification of chemical identity, purity levels (typically >99%), and screening for residual solvents or contaminants.
Sofosbuvir’s backbone allows several points for medicinal chemists to modify, aiming for improved metabolic stability, better absorption, or broader antiviral coverage. The initial design introduced a phosphoramidate prodrug element, which bypasses cellular bottlenecks that limited earlier analogues. Hydrolysis and enzymatic steps inside the body generate the active nucleotide triphosphate, which competes with the natural uridine substrate in the viral RNA polymerase. Researchers in both academia and industry continue to tinker with substitutions on the sugar or base, seeing potential for next-generation antivirals. Many generic manufacturers look closely at minor process tweaks, balancing patent requirements and access goals.
In scientific communication, sofosbuvir appears under its IUPAC designation but more commonly answers to its USAN name. Sovaldi rose as the original trademark from Gilead, while generics pick local registers like Hepcinat, Sofovir, or MyHep. Databases may record synonyms such as PSI-7977 (earliest code name), or GS-7977 (indicating Gilead’s internal tracking). Pharmacies and hospitals stock the compound by generic as well as all major brand variants, ensuring both provenance and flexibility in treatment.
Sofosbuvir enjoys a reputation for strong safety and easy integration into health system workflows. Packaging and handling must meet global pharmacovigilance requirements, with each lot traceable from synthesis to patient handoff. Most side effects remain mild (fatigue, headache). Combining with certain other antivirals, especially in regimens containing amiodarone, requires monitoring for bradycardia. Pharmacists note the need for accurate medication reconciliation, since co-administration with strong P-gp inducers (like rifampin or St. John’s wort) may drop sofosbuvir levels and reduce effectiveness. Storage in clinical settings keeps tablets cool, dry, and shielded from excessive light or humidity, reducing the risk of degradation.
Sofosbuvir’s profile makes it essential in chronic hepatitis C therapy, spanning multiple virus genotypes. Its oral delivery fits daily life for both newly diagnosed and treatment-experienced populations. Beyond HCV, some clinical research pushes the envelope, asking whether the same inhibition mechanism applies to other RNA viruses, particularly in public health emergencies like emerging viral outbreaks. In parts of the world with big hepatitis C backlogs, local production of generics brings this cure within reach for millions who would have once faced years, even decades, of progressive liver disease.
Ongoing development surrounding sofosbuvir moves on several fronts. Clinical scientists continue to pair it with other antivirals, targeting stubborn cases or people with advanced liver damage. Real-world studies look at resistance profiles, particularly in populations with high rates of co-infection (like HIV/HCV dual positive). The chemistry and process development sides explore ways to reduce production cost, stretch supply chains, and expand availability. Published studies in major journals note the relative simplicity of adherence, which supports both cure rates and population-level transmission drops. Investment returns for early developers reached billions, enabling further advances across the antiviral pipeline.
Preclinical work on sofosbuvir went beyond simple cell cultures, moving through animal models to detect carcinogenic or teratogenic signals. Initial findings showed strong safety margins, little off-target toxicity, and no major reproductive or developmental risks. Long term follow-up in patient cohorts hasn’t flagged serious unexpected side effects. Hepatic metabolism stands as the primary clearance mechanism, so people with severe liver impairment require close monitoring, though dose adjustments are rare. Pharmacovigilance keeps an eye out for rare allergic reactions or risks linked to polypharmacy in those with complex illness.
What comes next for sofosbuvir will shape access to hepatitis C cures for coming generations. Many expect continued price drops as more generics join the market, making treatment campaigns possible in regions once blocked by high costs. Combination therapy remains a hotbed—mixing sofosbuvir with newer direct-acting antivirals, aiming for single-tablet, even once-weekly regimens. Public health groups see a path toward population-wide HCV elimination, especially as screening and diagnostic technology catches up. Academic labs keep probing for ways to tweak the chemistry further, extending the impact to other viral infections. For healthcare providers and patients alike, sofosbuvir signals what’s possible with smart investment in pharmacology and open sharing of new treatments.
Sofosbuvir landed in medicine cabinets as a major leap for people with hepatitis C. Until its arrival, many folks who heard “hep C” sitting at their doctor’s office braced for rough months ahead. Old school medications drew out treatment, triggered nasty side effects, and still didn’t cure everyone. Then sofosbuvir came along and turned that story around.
Sofosbuvir targets the hepatitis C virus directly. It blocks an enzyme the virus relies on to copy itself, slamming the breaks on virus production in the liver. Instead of endless cycles of infections and flares, the body finally gets the upper hand. Clinical trials lined up proof: cure rates jumped above 90%. Fewer folks suffered through fatigue, fevers, or loss of appetite for months on end, because treatments lasted a fraction of the time and left most people smiling instead of feeling wrecked.
I’ve seen hepatitis C cast a long shadow on families. Years ago, people talked about avoiding liver failure or hoping transplant lists would move quickly enough. That fear still lingers in communities hit hardest by hepatitis C, especially among folks living with past injection drug use, people who received blood transfusions before the 90s, or incarcerated populations exposed to risky conditions. Sofosbuvir offers hope where there was none before — it doesn’t erase old regrets, but it gives people an honest chance at a healthy future.
Not everything about sofosbuvir feels perfect. The biggest complaint I hear — sometimes right outside local clinics — revolves around price. Sofosbuvir’s powerful outcomes drew headlines with its cost tag. Because of this, many people find themselves jumping through insurance hoops, dealing with payers who wrangle over forms, or sitting on waiting lists. Globally, millions can’t reach sofosbuvir because of price barriers or supply limits.
Pressure from patients, advocacy groups, and doctors does push companies to rethink prices. Some places struck deals for cheaper generics, bringing the drug to countries in Asia, Africa, and Eastern Europe. In my own community, outreach teams share honest information on free or low-cost clinics. Early diagnosis combined with simple, effective drugs can stop hepatitis C from haunting a new generation.
The World Health Organization wants hepatitis C gone as a major threat by 2030. Sofosbuvir will play a key part. Real progress happens in doctor’s offices, at mobile clinics, and in groups offering hepatitis C testing at recovery centers. People still wait for easier blood tests, fairer drug prices, and insurance policies built around healing instead of spreadsheets. The science behind sofosbuvir gives healthcare workers a fighting chance. Sharing that progress with those who need it most remains the real test.
Sofosbuvir stands as a key player for treating hepatitis C, a virus known for causing lasting harm to the liver. Doctors prescribe it as part of a combination plan, never on its own. My years working in pharmacy have shown me that many people feel anxious and overloaded once they see the names and schedules of these medications. Getting the details right truly matters for long-term health, and missing a step can set back progress.
Take sofosbuvir as a single tablet once each day, at the same hour. Pick a time you won’t forget—such as the morning before breakfast or evening before brushing your teeth. It does not matter whether you eat before or after. What counts is routine; patterns help you avoid skipped doses. Set an alarm or keep the medicine bottle by something you use every day. Missing even one dose lowers the treatment’s power and gives the virus a chance to survive.
Swallow tablets whole, with water. Chopping or crushing changes how your body absorbs the drug, risking side effects or less benefit. This may sound simple, but in my pharmacy practice, I’ve seen many try to break up pills to “make them easier.” It’s not worth the risk. If you struggle to swallow tablets, let your doctor or pharmacist know. Sometimes small things like changing your posture or using a pill-swallowing gel make a difference.
Even over-the-counter drugs and supplements interact with sofosbuvir. One standout example is St. John’s Wort, which lowers the amount of sofosbuvir in your system. The hepatitis C virus uses every chance, so you can’t afford to let its levels drop. Antacids and heartburn medications often make this list of drugs to avoid or space out. Never hesitate to bring your medication list to your appointments—pharmacists and doctors expect and appreciate these details.
Years on the job taught me that medication alone rarely solves health problems. Sticking to a nutrient-rich diet, avoiding alcohol, and getting steady exercise help the liver heal. Watch for tiredness, skin changes, or yellowing in your eyes, signs that the liver still struggles. These symptoms call for quick messages to your doctor, not waiting for your next visit.
Like most treatments, sofosbuvir often brings mild side effects: mild headaches, tiredness, or trouble sleeping. Serious problems show up less often, but they deserve fast action—continuous nausea, trouble breathing, new heartbeat changes. Years spent guiding patients show me that talking through symptoms early stops small issues from growing into big problems.
Missing doses lets hepatitis C build up defenses. Experts found that missing just one week can raise the risk of the virus hanging on. Studies in journals like Hepatology describe patients losing out on cure rates because they stopped too soon. This isn’t scare talk—it’s the truth. Your best shot at healing starts by locking down a routine and calling for help if snags pop up.
Sometimes the fear of hepatitis C can make even a simple plan feel overwhelming. Local pharmacists, support groups, and online programs lend real-world advice about keeping up. They share tricks for remembering pills, and can connect you to others who beat the same virus. Relying on this network isn’t a sign of weakness, but determination for health.
Sofosbuvir found its place on pharmacy shelves as a promising antiviral for hepatitis C. Doctors often see patients cheer the pill’s convenience, because it comes with fewer restrictions than older drugs. Still, people talk a lot about what to expect when starting treatment. Among the questions, “Will I feel side effects?” comes up over and over. After hearing from support groups and reviewing recent FDA updates, I have a good sense of the common troubles people see with sofosbuvir.
One thing I hear from patients in clinics and online forums—sofosbuvir makes you feel tired. Not the sleepy after-lunch tired, either. Some describe it as dragging through mud or carrying a weight on their shoulders. This isn’t rare: Upwards of 15-25% report this kind of fatigue, especially early in treatment. Some people try caffeine to power through, but many say pacing themselves works best. Physicians watch for anemia or low iron, since these can deepen fatigue for folks on combination therapies.
Headaches pop up as the next most common side effect. Patients who don’t usually get headaches may find themselves reaching for pain relievers more often. Most headaches are mild, but some stick around all day. Nausea follows close behind. Sometimes, it hits right after the dose, and other times it’s a slow, queasy feeling. People find relief by taking the pill with food or ginger tea, though prescription anti-nausea pills help for tougher days.
Sleep gets rough for some people using sofosbuvir. A few tell stories about lying in bed, wide-eyed at three a.m. Their minds can’t rest, or their bodies twitch and turn. This doesn’t hit everyone, but anyone feeling wired or anxious should mention it during check-ups. I’ve seen doctors suggest sleep routines, less caffeine, and sometimes even a light sleeping aid to keep things on track. Trouble focusing or memory lapses follow poor sleep, but these usually fade as the weeks go on.
Sofosbuvir can bring aches and pains in joints or muscles. Not crippling pain, but an annoying background hum. This effect seems stronger in folks over fifty, and in those who already struggle with arthritis or past injuries. Some people get relief from stretching or gentle exercise. Over-the-counter painkillers work, too, as long as liver health stays stable.
A handful of patients report rash, especially on the arms or torso. Oral antihistamines often calm the itch, but new rashes warrant a quick call to the doctor. Depression or anxiety can show up, even in those who never struggled with mood before. One out of every ten might feel down or short-fused by week six or seven. Regular mental health check-ins matter a lot for people at risk. Shortness of breath shows up less often, but doctors will look for anemia or other causes if it appears.
Everyone’s body reacts differently to new medicines, and sofosbuvir is no different. Hydration, balanced meals, steady routines, and regular exercise all make recovery smoother. A good relationship with the healthcare provider makes a difference, too. Bringing up new symptoms allows for quick fixes and avoids big disruptions. Reporting serious reactions to the FDA’s MedWatch program helps strengthen our understanding of these medications.
Sofosbuvir changed how we treat hepatitis C. Most people finish the course without anything more than mild annoyances. But tuning in to the signals our bodies give and tapping into medical support help keep small problems small. With more people sharing their stories, both patients and clinicians learn what to expect—and how to manage what comes up.
Sofosbuvir changed the game for hepatitis C treatment. Before it arrived, folks relied mostly on older drugs like interferon and ribavirin that came with a lot of side effects. Sofosbuvir works differently—it's a direct-acting antiviral, targeting the hepatitis C virus itself instead of just ramping up the immune system. More people started completing their treatment, and more lives saw actual improvement.
Most people with hepatitis C don’t take sofosbuvir alone. The virus has several strains, and only a tailored mix of drugs can clear it out for good. Doctors usually combine sofosbuvir with other medications such as ledipasvir or velpatasvir. These combinations block the virus at different steps in its life cycle. Studies back this up: clinical trials published in The New England Journal of Medicine showed that the cure rate soared above 90% with the right combo. Ledipasvir/sofosbuvir, known as Harvoni, became a symbol of this success, especially for people with genotype 1.
Relying on one drug makes it easier for the virus to find a way around the attack. Adding another direct-acting antiviral, with a slightly different target, keeps the virus in check. This stops it from building up resistance. In clinics, real people benefit—treatments get shorter, sometimes just 8 or 12 weeks. Some can even avoid ribavirin, dodging many of the rough side effects.
Combining is important for folks with co-infections or liver problems, too. Someone with HIV who has hepatitis C often ends up juggling lots of prescriptions. Sofosbuvir mostly plays well with other hepatitis C drugs, but drug-drug interactions can get tricky. That's where pharmacists become key, flagging doses or combinations that could clash. Regular blood work and open talks with a healthcare provider bring these issues to light before side effects start.
Online forums and advice from friends feel accessible, but only a provider checks your kidney function or digs into your medication list. People often don’t realize that generic antivirals bought from unregulated sources can mess up progress or carry impurities. Medical teams stick with combinations that got the green light from groups like the American Association for the Study of Liver Diseases and Infectious Diseases Society of America. These guidelines change as new data rolls in, keeping treatment safe and up-to-date.
Insurance and cost aren’t sideline issues. Sofosbuvir packs a big price tag. Some insurance companies push for cheaper combinations or older drugs. For low-income patients, patient-assistance programs can bridge gaps, but only if someone knows to ask. Social workers and case managers can help families navigate this maze and find the right program.
New drugs join the list every year. Researchers in 2023 published trials that support even shorter courses with fewer pills. This gives hope to folks who couldn’t tolerate previous options or who stopped because of the side effects. The main challenge isn’t the science—it’s getting the word out, getting access, and making sure patients and providers work together.
Staying informed helps people advocate for themselves. The power of combination therapy, built on years of trials and direct feedback from patients, works best in real life when people stick to the plan and have support. Sofosbuvir works wonders, but only as part of a team.
Sofosbuvir has earned its place in the fight against hepatitis C. People see it as a sort of modern miracle—just a pill a day, no need for interferon shots, fewer side effects for most people, often a cure within a few months. Yet it comes with real limitations. The kidneys process part of the drug. Anyone with severe kidney impairment, especially those with end-stage kidney disease or on dialysis, runs into trouble. Their bodies can’t clear the drug properly. Levels rise, side effects may hit harder, even reach dangerous levels. According to the FDA, safety in people with serious kidney disease remains unproven. Many of these folks need different medicine or a specialized approach guided by a nephrologist and liver specialist.
Pregnancy brings hope, so every parent wants to avoid risks that threaten their baby’s life and health. Sofosbuvir falls in the same category as many new antiviral drugs: not enough studies, plenty of unknowns. Animal research hints at miscarriages, but human data remain scarce. Doctors recommend women planning to get pregnant wait until treatment ends. The question runs deeper for breastfeeding; since it’s not clear whether the medicine passes into milk, most guidelines steer new mothers away from sofosbuvir while feeding their infants. This protects the baby from any possible unknown harm.
Combining sofosbuvir with certain drugs can create problems. Amiodarone, a drug for irregular heartbeats, stands out as a big red flag. Taken together, even in the same week, people have lost consciousness or nearly died because severe bradycardia—slowed heartbeat—kicked in. Drug information sheets carry a heavy warning for this combination.
Strong rifampins, certain seizure medications like carbamazepine, and even St. John’s Wort change how sofosbuvir gets broken down. These drugs lower sofosbuvir levels, so there’s not enough medicine left to cure hepatitis C. People often don’t know herbal remedies can matter just as much as prescription pills. Checking with a pharmacist or medical provider avoids these mistakes.
A small group reacts badly to sofosbuvir. Serious allergic reactions can start the first time, or even after a few doses: rash, swelling, trouble breathing. I’ve seen patients who had to stop taking it in the hospital, because just a few hives can turn into a full emergency. People who notice new swelling or severe rashes need help right away. Those who reacted to sofosbuvir before should never try it again, even if their hepatitis C comes back.
Doctors individualize treatments for hepatitis C. Before writing a prescription, physicians run blood tests to check kidney function, review a person’s medication list, look at allergies, and talk about pregnancy goals. Pharmacies play their part, too, flagging possible interactions and reminding patients about herbal risks. Managed care teams can help coordinate these checks. People have a role to play: keeping providers updated about any new drugs, supplements, or life changes. Better communication keeps treatment effective and safe, letting more people beat hepatitis C without extra risks.
| Names | |
| Preferred IUPAC name | Isopropyl (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate |
| Other names |
PSI-7977 GS-7977 |
| Pronunciation | /soʊˈfɒs.bjuː.vɪər/ |
| Identifiers | |
| CAS Number | 1190307-88-0 |
| 3D model (JSmol) | `3D model (JSmol)` **string** for **Sofosbuvir**: ``` CC(C)COC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@@](C#N)(c2ccc(F)cc2)C[C@@H](O)[C@H]1O)Oc1ccccc1 ``` |
| Beilstein Reference | 3858736 |
| ChEBI | CHEBI:90961 |
| ChEMBL | CHEMBL1257073 |
| ChemSpider | 21589543 |
| DrugBank | DB08934 |
| ECHA InfoCard | 100.221.854 |
| EC Number | EC 2.7.7.7 |
| Gmelin Reference | 104066 |
| KEGG | D09721 |
| MeSH | D013375 |
| PubChem CID | 45375808 |
| RTECS number | RG2TCJ545A |
| UNII | Q1VWU83A4G |
| UN number | UN3373 |
| Properties | |
| Chemical formula | C22H29FN3O9P |
| Molar mass | 529.45 g/mol |
| Appearance | White to off-white, crystalline solid |
| Odor | Odorless |
| Density | 2.0 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 1.62 |
| Vapor pressure | 0.0 mmHg at 25°C |
| Acidity (pKa) | 9.38 |
| Basicity (pKb) | pKb = 9.3 |
| Magnetic susceptibility (χ) | -72.3 × 10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.665 |
| Dipole moment | 2.61 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 312.5 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | ΔfH⦵298 (Sofosbuvir) = -1149.2 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -9155 kJ/mol |
| Pharmacology | |
| ATC code | J05AP08 |
| Hazards | |
| Main hazards | May cause liver problems, fatigue, headache, severe allergic reactions, bradycardia (especially with amiodarone), and potential for hepatitis B reactivation. |
| GHS labelling | GHS labelling of Sofosbuvir: `"Not classified as hazardous according to GHS"` |
| Pictograms | `L01BA05` |
| Signal word | No signal word |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | P101 If medical advice is needed, have product container or label at hand. P102 Keep out of reach of children. P103 Read label before use. |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 1, Instability: 0, Special: - |
| Flash point | > 263.5 °C |
| Autoignition temperature | Autoignition temperature: 420°C |
| Lethal dose or concentration | LD50 >2000 mg/kg (rat) |
| LD50 (median dose) | > 2000 mg/kg (rat, oral) |
| NIOSH | NF3500000 |
| PEL (Permissible) | Not assigned |
| REL (Recommended) | 400 mg once daily |
| IDLH (Immediate danger) | Not Established |
| Related compounds | |
| Related compounds |
Remdesivir Uprifosbuvir Adafosbuvir Dasabuvir |
